Defined Health is a leading business development strategy consulting firm. We’ve been assisting clients in the pharmaceutical, biotech and healthcare investment industries for more than 25 years.

  • Defined Health has three core lines of business, each focused on helping companies build and strengthen development-stage assets; compounds, portfolios and platforms
  • A key differentiator is the firm’s focus on defining value for early stage compounds as “proof of relevance” (“PoR”), looking beyond mechanistic proof-of-concept to demonstrate clear potential for clinical differentiation and indisputable commercial value
  • Defined Health’s position of trust can be leveraged for the long term, across the continuum of clinical development and “go to” market services
Opportunity Assessments Portfolio and Platform Strategy Identification and Evaluation of In-Licensing Opportunities
  • Validate scientific rationale
  • Position in evolving standard of care
  • Define target patient populations, clinical endpoints and target product profiles
  • Determine payer perspective
  • Assess commercial value
  • Analyze and prioritize pipeline portfolio
  • Identify and assess novel indications for development
  • Prioritize potential indications
  • Define value inflection strategy for clinical candidates
  • Advise on optimal time and stage of development for partnering
  • Advise on partner selection
  • Establish criteria for identifying programs that fit with strategy
  • Identify assets and/or companies that best match criteria
  • Provide deeper analysis of priority targets
  • Identify value inflection points to optimize partnering strategy
  • Leverage extensive industry network to identify potential strategic partners

Our experience means each new project starts from a solid foundation of knowledge – deep in the therapeutic area, wide in application. Over the past two decades, Defined Health has helped to assess the value of many of the industry's headline partnering deals.

We differ from other consulting firms in our unique depth and breadth of experience, in our people, and in the quality of our client interactions. The key to what we have come to call our unconventional insight is our unparalleled therapeutic area experience.

What's New - Clients in the news

Boosting Immuno-Oncology Therapies to the Next Level: New Combinations & Approaches
July 23rd, 2015

Moderators: Jeffrey M. Bockman, PhD, Vice President
Defined Health

Joel Sandler, PhD, Consultant
Defined Health

Panelists: Michael Curran, PhD, Assistant Professor, Department of Immunology; Scientific Director, ORBIT Program, MD Anderson

Rachel Humphrey, MD, Vice President, Head of Immuno-Oncology, Eli Lilly and Company

Web Panel Discussion: What's Hot & What's Not in Gene Therapies for Rare Disorders
May 6, 2015

Moderator: Michael C. Rice, MS, MBA Senior Consultant
Defined Health

Matthew Porteus, MD Associate Professor of Pediatrics
(Cancer Biology), Stanford University

Paul Gallagher, MBA President, Compass Strategic Consulting

Stewart Abbot, Ph.D Executive Director, Integrative Research at Celgene Cellular Therapeutics (CCT)

Changes to Biopharma’s External Ecosystem That Will Bring Permanent Changes to the Biopharmaceutical Industry
April 30th, 2015

Ed Saltzman, President
LES-NJ Chapter Meeting
Basking Ridge, NJ

Actavis confirms timeline for the start of phase III development of abicipar

Former Teva CEO Levin to Lead Startup Focused on Brain Diseases
Teva Pharmaceutical Industries Ltd

Eli Lilly and Company: Lilly, Bristol-Myers Squibb Restructure Erbitux® (cetuximab) Collaboration in North America
Eli Lilly

AbbVie moves closer to Japan's crowded hep C field with priority review nod



BioPharm America
September 15 - 17, 2015 | Boston, MA

CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Surviva
September 16 - 19, 2015 | New York, NY

GTCbio's CNS Partnering & Deal-Making Conference
September 18 - 19, 2015 | Philadelphia, PA

LES 2015 Annual Meeting
October 25 - 28, 2015 | New York NY

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
November 5 - 9, 2015 | Boston, MA

Cancer Progress by Defined Health
Mar 08 - Mar 09, 2016 | New York, NY

Therapeutic Insight by Defined Health
Apr 04 - Apr 06, 2016 | Stockholm, Sweden


Therapeutic Insight by Defined Health Cancer Progress by Defined Health